Lurbinectedin is a chemotherapy drug that is used to treat small cell lung cancer (SCLC) that has progressed after initial chemotherapy treatment. However, the safety of Lurbinectedin for patients with low white blood cell counts is unclear based on the provided sources.

The drug label provided by the FDA [3] mentions that patients with a history of low white blood cell counts should be monitored closely while taking Lurbinectedin. Additionally, the label lists a number of potential side effects of the drug, including a decrease in white blood cell count, which can increase the risk of infection.

The Zepzelca website [2] also lists a decrease in white blood cell count as a potential side effect of the drug. However, it does not provide specific information on the safety of Lurbinectedin for patients with low white blood cell counts.

The Drug Patent Watch website [1] provides information on the patent status of Lurbinectedin but does not provide any information on the drug's safety or side effects.

In conclusion, based on the provided sources, it is unclear whether Lurbinectedin is safe for patients with low white blood cell counts. Patients with a history of low white blood cell counts should be closely monitored while taking Lurbinectedin, and they should discuss the potential risks and benefits of the drug with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.zepzelca.com/zepzelca-side-effects/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf